Compare PRK & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRK | TLX |
|---|---|---|
| Founded | 1908 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 1996 | N/A |
| Metric | PRK | TLX |
|---|---|---|
| Price | $172.04 | $9.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $184.00 | $21.13 |
| AVG Volume (30 Days) | 63.3K | ★ 130.5K |
| Earning Date | 04-24-2026 | 08-19-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $664,421,000.00 | N/A |
| Revenue This Year | $24.26 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | ★ $72.37 | $150.33 |
| Revenue Growth | ★ 2.92 | N/A |
| 52 Week Low | $149.06 | $6.28 |
| 52 Week High | $179.48 | $17.25 |
| Indicator | PRK | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 44.55 |
| Support Level | $169.82 | $9.46 |
| Resistance Level | $176.73 | $9.92 |
| Average True Range (ATR) | 3.25 | 0.24 |
| MACD | 0.16 | -0.13 |
| Stochastic Oscillator | 91.92 | 39.71 |
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.